For patients
Oncotype DX Breast Recurrence Score® test
Gain insight to help make more informed decisions
The only test proven to be prognostic of distant recurrence and predictive of chemotherapy benefit1-4
Is this test right for you?
For patients that have recently been diagnosed with node-negative or node-positive HR+ means hormone receptor-positive, which means that tumor cells have receptors for estrogen or progesterone.HR+ and HER2 means human epidermal growth factor receptor 2, a protein that controls cell growth and division.HER2- invasive breast cancer that are medically eligible for chemotherapy.
Sample type
This test uses tumor tissue that’s already been collected during your biopsy or at the time of surgery.
Outcome
You’ll get a clear indication of your risk of cancer returning, and if adding chemotherapy to your treatment plan will benefit you.1-4
Answering your biggest questions
How likely is my cancer to come back? Will chemotherapy help?
Every patient is different and so is every tumor. The Breast Recurrence Score test uses The study of the complete set of DNA (including all of its genes) in a person or other organism.genomic information to give you and your doctor important risk information about how your individual tumor will likely behave. Find out:
Your individual risk of cancer returning in another part of your body3,4
How likely you are to benefit from adding chemotherapy to your hormone therapy treatment1,2
Is this test right for me?
If you’ve been diagnosed with HR+, HER2- invasive breast cancer, the Oncotype DX Breast Recurrence Score test may offer you valuable insights to help guide your treatment decisions. Talk to your doctor to learn more.
Will insurance cover my test?
The Breast Recurrence Score® test is included in all major breast cancer treatment guidelines, and is for newly diagnosed HR+, HER2- breast cancer patients with Stage I-IIIA, node-negative or node-positive disease.5-11 It is covered by many major insurance companies. In fact, 91% of Breast Recurrence Score test patients paid less than $100 — and 86% of patients paid nothing at all.*
Proven results help prevent over-treatment
1.8 million
Over 1.8 million patients with early-stage invasive breast cancer have trusted the Breast Recurrence Score test to help guide their treatment decisions.†
1.48 million
1.48 million of them had a low risk of recurrence which meant that adding chemotherapy did not reduce their risk any further.†
A breast surgeon and mother, diagnosed with invasive breast cancer
Link copied
Deepa H.
Facing cancer helped her understand her patients better
Node-negative invasive breast cancer
Recurrence Score® result: 18
Deepa’s diagnosis
While on spring break with her family, Deepa felt pain in the right side of her chest. After a mammogram revealed a mass in her breast, she immediately got an ultrasound and biopsy. At 41, Deepa, a new breast surgeon was diagnosed with invasive breast cancer.
Facing difficult choices
Like most patients, Deepa was devastated with the diagnosis and what it could potentially mean for her career as a breast surgeon. She was faced with the same decision her patients had to make - whether to get a lumpectomy or mastectomy, and whether or not she would need chemotherapy.
As a surgeon, she knew a lumpectomy would also include radiation with potential side effects - something she had seen first-hand with her patients. Ultimately, Deepa decided on a mastectomy with reconstruction.
"All of this has allowed me to gain a unique perspective from being a breast cancer surgeon and breast cancer patient. Now I know what it's like to face cancer. I have walked in my patients' shoes.“
Her test results
After her mastectomy, the pathology results showed that she had a 1.5cm tumor. Deepa immediately knew that she would request an Oncotype DX Breast Recurrence Score test.
The results came back with a Recurrence Score result of 18 meaning her benefit from chemotherapy would be low, and she decided not to do chemotherapy.
Deepa’s path forward
After this experience, she recognizes that there are real people behind the statistics that doctors give to patients. Deepa now calls her patients as soon as their results come in because she understands their anxiety when waiting for answers. Deepa ensures that when she has discussion with her patients, they have a shared decision-making process about treatment and that her patients are empowered to ask the right questions when they see a medical oncologist.
This story reflects one individual’s experience. Not every person will have the same treatment, experience, or outcome. Talk to your health care provider about whether this test may be right for you.
What happens once your doctor orders your test?
Your Breast Recurrence Score test is performed on tumor tissue that’s already been removed from your breast during your biopsy or at the time of surgery.
Have questions?
Call us at 1 866-662-6897 .
References
- This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patients with high-deductible plans may receive a bill for most or all the cost of the Breast Recurrence Score test if they have not satisfied their deductible. The numbers cited are based on historical patient billing data from 1/2/2024 to 12/31/2024. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages your patient to contact their insurer with questions about Oncotype DX Breast Recurrence Score test coverage.
- Data on file
- Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
- Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
- Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829-1834.
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
- Referenced with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Breast Cancer V.6.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed December 23, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541-1557.
- National Institute for Health and Care Excellence (NICE) Guidelines. Tumor profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Published May 9, 2024. Accessed December 23, 2024. https://www.nice.org.uk/guidance/dg58.
- Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early- stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(16):1816-1837.
- AGO Breast Committee. Diagnosis and Treatment of Patients with early and advanced Breast Cancer. Version 2024. 1E. Accessed December 23, 2024. https://www.ago-online.de/fileadmin/ago-online/
downloads/_leitlinien/ .kommission_mamma/2024/englisch/Einzeldateien /AGO_2024E_26_Therapy_algorithms.pdf - Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220.
- Hortobagyi GN, Connolly JL, D’Orsi CJ, et al. Breast. In: AJCC Cancer Staging Manual. 8th ed. Amin MB et al, eds. Cham, Switzerland: Springer; 2017.
The Oncotype DX Breast Recurrence Score test is performed at the Genomic Health Redwood City clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the US Food and Drug Administration.